# JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

> **NCT06586866** · PHASE2 · NOT_YET_RECRUITING · sponsor: **JenKem Technology Co., Ltd.** · enrollment: 25 (estimated)

## Conditions studied

- Triple Negative Breast Cancer (TNBC)
- Brain Metastasases

## Interventions

- **DRUG:** JK-1201I

## Key facts

- **NCT ID:** NCT06586866
- **Lead sponsor:** JenKem Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-26
- **Primary completion:** 2026-05-26
- **Final completion:** 2026-10-26
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06586866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06586866, "JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06586866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*